Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Open-Label, 4-Cohort Study of Nogapendekin Alfa Inbakicept in Combination With Current Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

NCT03520686 is registered in ClinicalTrials.gov with ImmunityBio, Inc. as lead sponsor.

NCT NCT03520686
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03520686 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Open-Label, 4-Cohort Study of Nogapendekin Alfa Inbakicept in Combination With Current Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Lead sponsor
ImmunityBio, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
May 18, 2018
Completion date
October 13, 2025
Enrollment
102 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer